A 43-year-old white male was referred to the Emergency Department with acute onset of severe dyspnea, cyanosis, and dry cough. He previously underwent a left-foot amputation in 2011 for synovial-sarcoma. In 2012, the patient experienced a relapse with bilateral lung metastases (Fig [1](#fig01){ref-type="fig"}) and, two months before admission, he started Pazopanib (Votrient, Glaxo Group Ltd, Brentford, UK) treatment. On day 72, a chest X-ray (Fig [2](#fig02){ref-type="fig"}) revealed a large right spontaneous pneumothorax (PNX) simultaneously associated to a left one. Thus, a 24 Fr chest tube was placed on each side providing immediate improvement of his clinical condition (Fig [3](#fig03){ref-type="fig"}). No signs of air leakage were discovered during hospitalization; therefore, the patient was discharged on the sixth post-operative day without consequence. Four days after discharge, he experienced a sudden swelling of the chest wall and moderate dyspnea. A chest computed tomography scan revealed a massive pneumomediastinum associated to large subcutaneous emphysema of the chest wall soft tissues (Fig [4](#fig04){ref-type="fig"}). After the second admission, a multidisciplinary meeting was performed and Pazopanib administration was ceased. His hospital course was unremarkable and seven days later he was discharged after regression of symptoms and complete radiological resolution.

![Computed tomography (CT) scan performed one month before commencing Pazopanib therapy. The exam disclosed bilateral lung metastases from synovial-sarcoma.](tca0006-0110-f1){#fig01}

![Chest X-ray revealed a spontaneous bilateral pneumothorax, greater on the right side.](tca0006-0110-f2){#fig02}

![Chest X-ray (performed after double chest tube insertion) disclosed the resolution of bilateral pneumothorax with no signs of pneumomediastinum.](tca0006-0110-f3){#fig03}

![Chest computed tomography (CT) scan revealed a massive pneumomediastinum associated to a large subcutaneous emphysema of the chest wall soft tissues.](tca0006-0110-f4){#fig04}

Simultaneous bilateral spontaneous PNX represents 0.9--4.0% of all spontaneous PNX;[@b1] moreover, PNX secondary to lung metastases is not commonly reported in literature. Although angiogenesis-inhibitor therapy (AIT) is known to cause tumor cavitation and "therapeutic erosion" of lung metastases,[@b2] PNX incidence was rarely reported in AIT clinical trials.[@b3],[@b4] Bilateral spontaneous PNX (Fig [2](#fig02){ref-type="fig"}) is an extremely rare and life-threatening condition that clinicians should immediately treat (by chest tube insertion and respiratory care, Fig [3](#fig03){ref-type="fig"}) during follow-up of metastatic patients under Pazopanib. Contrary to reports by other scholars,[@b4] an association with pneumomediastinum (Fig [4](#fig04){ref-type="fig"}) caused by an erosion of lung metastases closer to the mediastinum is even rarer; when this condition occurs, a multidisciplinary evaluation (with oncologist, pneumologist, and thoracic surgeon) is required in order to undertake a conservative treatment (and the ceasing of drug administration).

In conclusion, although it rarely occurs, the onset of an air leak (PNX or pneumomediastinum) during Pazopanib treatment is a life-threatening condition related to lung metastases erosion. Thus, a close clinico-radiological examination is mandatory in pulmonary metastatic patients under AIT.
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